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Received December 25, 2011; accepted May 29, 2012AbstractBackground: The proper use of endorectal coil MRI (eMRI) images provide detailed information for the real extent of locally prostate cancer
invasion and involvement of pelvic lymph nodes. This study evaluated the accuracy of endorectal coil magnetic resonance imaging (eMRI)
results, combining the preoperative prostate-specific antigen (PSA), and the biopsy Gleason score to improve the diagnostic accuracy of prostate
cancer (PCa) with organ-confined disease (OCD) or extracapsular extension (ECE)/seminal vesicle invasion (SVI).
Methods: Between 2001 and 2007, 94 PCa patients received eMRI testing during presurgical evaluation and underwent radical prostatectomy. As
a part of routine patient workup, serum PSA level and Gleason score after pathology examination were recorded. The eMRI images were used to
help assess patient PCa staging status regarding OCD or ECE/SVI. These stage assessments as evaluated through the use of MRI were compared
with the final specimen pathological stage after the patients underwent radical prostatectomy.
Results: Of the total 94 patients in our study, 65 had stage pT2, 12 had stage pT3a, and 17 had stage pT3b PCa. In patients with clinical stage T2
PCa, the Gleason score significantly improved the discriminative ability of eMRI to successfully predict PCa at the OCD stage. Otherwise, in
cases of clinical stage T3 PCa, accurate determination of PSA levels significantly improved eMRI predictive ability to assess ECE or SVI
staging.
Conclusion: In clinical stage T2 PCa patients, integrating the biopsy Gleason score improved the discriminative ability to assess OCD PCa
staging. Additionally, combining the preoperative PSA levels of clinical T3 prostate cancer cases with Gleason scores significantly improved the
sensitivity and accuracy of eMRI diagnosis to distinguish ECE from SVI.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Accurate staging is critical for the treatment and prognosis
of patients with prostate cancer (PCa). The choice of an
effective treatment modality for organ-confined disease (OCD)* Corresponding author. Dr. Tai-Lung Cha, Division of Urology, Department
of Surgery, Tri-Service General Hospital, 325, Section 2, Cheng-Gung Road,
Neihu, Taipei 114, Taiwan, ROC.
E-mail address: tlcha@ndmctsgh.edu.tw (T.-L. Cha).
1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.09.005or locally advanced PCa remains controversial. If extrac-
apsular extension (ECE) can be accurately identified before
surgery, the ipsilateral neurovascular bundle can be either
preserved to maintain organ function, or widely excised in
order to prevent positive surgical margins. If seminal vesicle
invasion (SVI) can be accurately identified, alternative treat-
ments such as radiation therapy or hormone therapy may be
preferable to surgical intervention. However, the current
methods used to distinguish precisely between clinically OCDhinese Medical Association. All rights reserved.
Table 1
Characteristics of 94 PCa between preoperative eMRI diagnosis and post-
operative pathologic stage.
Preoperative
parameter
Pathologic finding p
T2 (n ¼ 65) T3a (n ¼ 12) T3b (n ¼ 17)
Mean age (y) 67.60  7.40 73.25  6.40 64.80  7.10 0.583
PSA (ng/mL) 12.08  8.61 20.85  18.61 33.32  30.00 <0.01
Gleason grade 3.12  0.65 3.50  0.80 3.82  0.88 <0.01
Gleason score 6.42  1.20 7.42  1.44 7.41  1.62 <0.01
MRI finding <0.01
T2 41/58 (70.7) 9/58 (15.5) 8/58 (33.3)
T3a 21/27 (77.78) 3/27 (11.1) 3/27 (11.1)
T3b 3/9 (33.3) 0/9 (0) 6/9 (66.7)
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suboptimal. Endorectal coil magnetic resonance imaging
(eMRI) offers the single most valuable imaging capability to
assess OCD or locally advanced diseases. However, the
accuracy of eMRI in evaluation of OCD or localized PCa has
been varied. It has been shown that up to 40% to 50% of
patients with clinically determined OCD PCa have, based on
eMRI results, undergone radical prostatectomy, but were
subsequently identified as having locally advanced dis-
eases.1e4 Conversely, about 20% to 25% of patients receiving
radiotherapy or undergoing androgen deprivation therapy were
overstaged by eMRI, and consequently lost the opportunity to
undergo radical surgery to cure the disease.5,6 In order to
improve the diagnostic accuracy of eMRI in distinguishing
OCD or ECE/ SVI, we investigated the diagnostic capability
of eMRI testing by integrating preoperative prostate-specific
antigen (PSA) level and patient Gleason score, to compare
the final results of pathological examination with OCD or
locally advanced prostate cancers.
2. Methods
Between January 2001 and October 2007, a total of 461
patients who came to our hospital were diagnosed with PCa.
The indications of transrectal ultrasound prostate biopsies
included elevated PSA, or a palpable nodule of the prostate.
All patients underwent bilateral prostatic biopsies with an 18-
gauge spring-loaded biopsy gun with 10 to 12 core biopsies.
One-hundred and sixty patients underwent eMRI for staging.
Based on clinical criteria (age, performance status, comor-
bidity, chest X-ray) and standard preoperative tests (PSA and
bone scan), 94 of the 160 patients were selected for surgery,
with a mean PSA level of 16.92 (0.12e107) ng/mL. The eMRI
procedure was carried out using a 1.5 T MRI unit with T2- and
T1-weighted images before and after gadolinium enhancement
(Magnetom Vision 1.5T; Siemens, Munich, Germany).
Written informed consent was obtained from all patients and
the study protocol was approved by the appropriate ethics
committees.
A low-signal-intensity lesion on T2-weighted images was
regarded as the indicator for prostate neoplasm. The appear-
ance of irregular contour deformity, asymmetry of the neuro-
vascular bundles, and obliteration of the recto-prostatic angle
were indicative of capsular penetration. Similarly, SVI pre-
sented as a low-signal-intensity infiltration of these structures;
whereas on T2-weighted images of noninvasion, SVI pre-
sented with a bright signal as a result of the fluid content. In
addition to postbiopsy lesion assessment, hematoma can be
differentiated from prostate neoplasm by their corresponding
appearance on T1-weighted eMRI.
In all cases, the waiting period between prostate biopsies
and eMRI study was maintained at an interval of >6 weeks in
order to reduce the likelihood of a false positive MRI study.
None of the above PCa patients had received hormone or
pelvic radiation therapy. Serum PSA levels and Gleason
grades were recorded. All the eMRI images were interpreted
by a single radiologist with expertise in the field of urology.All surgical interventions involving radical prostatectomy
were completed no more than 2 weeks after eMRI studies
were completed. The preoperative eMRI results were corre-
lated with the final histopathological findings after patients
underwent radical prostatectomy.3. Results
Data were collected from a total of 94 consecutive patients
with clinically localized PCa who underwent preoperative
eMRI studies, and the correlation with the final staging
assessments after pathological examination was analyzed. The
average age of subjects was 68.9 (50e85) years. There were
58 patients included with clinical stage T2, 27 with clinical
stage T3a, and nine with clinical stage T3b PCa. The final
histopathological results showed that a total of 65 subjects
were diagnosed with stage pT2, 12 with pT3a, and 17 with
stage pT3b PCa (Table 1). The age distribution was not
significantly different among different stage PCa. According
to the diagnostic results of eMRI, the preoperative PSA levels
and Gleason scores were statistically lower in pT2 than pT3a
or pT3b PCa ( p < 0.001). The sensitivity rates of eMRI in
identifying OCD, ECE, and SVI were 63.08%, 25.0%, and
35.29%, respectively. The specific rates of eMRI in dis-
tinguishing OCD, ECE, and SVI were 41.38%, 70.73%, and
96.10%, and the accuracy in differentiating OCD, ECE, and
SVI were 56.38%, 68.09%, and 85.11%, respectively.
The patients were divided into three groupsdthose with
cT2, cT3a, and cT3b PCa casesdaccording to the eMRI
diagnosis. The preoperative Gleason grade and serum PSA
were investigated as to enhance the prognostic efficiency of
eMRI for differentiation of localized and locally advanced
PCa (Table 2). Of the preoperatively diagnosed cT2 PCa,
70.69% (41/58) cases were later proved to be pT2 stage, and
29.31% (17/58) as pT3 stage, which meant that 29.31% of the
cases were understaged by a single imaging tool (eMRI). In
the cT3a PCa cases, 77.78% (21/27) were later proved to be
pT2 as OCD, 11.11% (3/27) to be pT3a as ECE, and 11.11%
(3/27) to be pT3b as SVI. Most cT3a PCa cases diagnosed by
eMRI were overstaged. In other cT3b PCa cases, 33.33% (3/9)
were diagnosed to be pT2 as OCD and 66.7% (6/9) to be pT3b
as SVI. The proportion of cT3b PCa cases overstaged by the
diagnostic tool of eMRI was 33.33%.
Table 2
Comparisons of PSA level and Gleason grade in the diagnostic power of PCa
pathologic stage between cT2 and cT3 patients.
Pathologic finding p
pT2 n (%) pT3 n (%)
cT2 patients (n ¼ 58)
PSA level
<10 22 (53.7) 9 (52.9) 0.512
10 19 (46.3) 8 (47.1)
<15 30 (73.2) 10 (58.8) 0.354
15 11 (26.8) 7 (41.2)
<20 37 (90.2) 13 (76.5) 0.334
20 4 (9.8) 4 (23.5)
Gleason grade 0.001
3 37 (90.2) 8 (47.1)
>3 4 (9.8) 9 (52.9)
Gleason score 0.138
7 37 (90.2) 12 (70.6)
>7 4 (9.8) 5 (29.4)
cT3 patients (n ¼ 36)
PSA level
<10 10 (41.7) 0 (0) 0.015
10 14 (58.3) 12 (100)
<15 15 (62.5) 1 (8.3) 0.004
15 9 (37.5) 11 (91.7)
<20 19 (79.2) 2 (16.7) 0.001
20 5 (20.8) 10 (83.3)
Gleason grade 0.081
3 16 (66.7) 4 (33.3)
>3 8 (33.3) 8 (66.7)
Gleason score 0.148
7 17 (70.8) 5 (41.7)
>7 7 (29.2) 7 (58.3)
Table 3
Comparisons of different cutoffs of PSA in diagnosis of the pathologic stage
between cT3a and CT3b PCa.
Pathologic finding p
T2 n (%) T3a n (%) T3b n (%)
cT3a patients (n ¼ 27)
PSA level
<10 9 (42.9) 0 (0) 0 (0) 0.058
10 12 (57.1) 3 (100) 3 (100)
<15 12 (57.1) 1 (33.3) 0 (0) 0.087
15 9 (42.9) 2 (66.7) 3 (100)
<20 16 (76.2) 1 (33.3) 1 (33.3) 0.032
20 5 (23.8) 2 (66.7) 2 (66.7)
cT3b patients (n ¼ 9)
PSA level
<10 1 (33.3) 0 (0) 0 (0) 0.333
10 2 (66.7) 0 (0) 6 (100)
<15 3 (100) 0 (0) 0 (0) 0.012
15 0 (0) 0 (0) 6 (100)
<20 3 (100) 0 (0) 0 (0) 0.012
20 0 (0) 0 (0) 6 (100)
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the Gleason grade from biopsy report had statistically signif-
icant correlation with the pathologic stages ( p ¼ 0.002).
However, the same population integrating preoperative PSA
level showed no statistical relationship between the eMRI
findings and final pathological stages. On the other hand, in
the cT3a/cT3b PCa cases, the preoperative PSA levels, but not
the Gleason grade, revealed a statistically significant correla-
tion between eMRI findings and final pathologic stages,
respectively (Table 3; p ¼ 0.032, p ¼ 0.012). In cT3a and
cT3b PCa cases with PSA levels above 20 ng/ml and 15 ng/ml,
respectively, the eMRI findings significantly correlated with
the final pathological stages. These parameters were compared
to improve the eMRI diagnostic accuracy involving capsule
invasion. The area under receiver operating characteristic
curves of the Gleason score and grade had a larger area than
the PSA level, with statistical significance in the clinical T2
stage. However, the under receiver operating characteristic
curve area of PSA has a significantly larger area than Gleason
score and grade in the clinical T3 stage (T3a and T3b) cases
(Fig. 1; Tables 4ae4b).
For patients with cT2 PCa, combining the parameters of
Gleason Grade 3 with the eMRI findings improved the
sensitivity of the staging capability of eMRI from 63.08% to
90.24% ( p ¼ 0.004), specificity from 41.38% to 52.94%
( p ¼ 0.65), and accuracy from 56.38% to 82.76%( p ¼ 0.007). For patients with cT3a PCa, we also noticed that
using 10 ng/ml of preoperative PSA as a cut-off significantly
increased the sensitivity of eMRI from 25% to 100% but
specificity and accuracy were compromised. In cT3b patients
with preoperative serum PSA levels above 15 ng/ml, the eMRI
showed high sensitivity (100%), specificity (100%), and
accuracy (100%). Overall, for the patients with cT3 PCa,
combining the PSA level above 15 ng/ml to improve the
sensitivity of eMRI diagnoses from 41.38% to 91.7%
( p ¼ 0.004), specificity from 63.08% to 62.5% ( p ¼ 0.96),
and accuracy from 56.38% to 72.2% ( p ¼ 0.099). In the same
population, combining the PSA level above 20 ng/ml with the
eMRI findings improved sensitivity from 41.38% to 83.33%
( p ¼ 0.035), specificity from 63.08% to 79.17% ( p ¼ 0.237),
and accuracy from 56.38% to 80.56% ( p ¼ 0.019).4. Discussion
Accurate staging of PCa is crucial for guiding appropriate
definitive treatment. Endorectal coil MRI is one of the most
effective pre-treatment staging methods available for dis-
tinguishing between clinically localized and locally advanced
prostate cancers. MRI can accurately detect locally advanced
prostate cancer in 56% to 86% of cases.7e12 Factors
responsible for this variation may include patient population
size, use of an endorectal coil, MR sequences, and reader
experience.13 Our study was conducted to survey the
comparisons between eMRI results and final pathologic
stages by integrating the Gleason grade from biopsies and
serum PSA levels.
One of the pivotal factors contributing to the accuracy ofMRI
detection in PCa is tumor size. Typically, tumor size is related to
the risk of extracapsular spread,14 relapse after radical prosta-
tectomy15 and PSA progression16: the larger the tumor, the
higher the risk of treatment failure. Previous studies have shown
Fig. 1. The receiver operating characteristic curve of clinical stage T2 (left) and T3 (right) patients.
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of6.17 Such tumors are likely to be indolent. This suggests that
the tumor size cutoff of 4 mm in diameter is sufficient to detect
significant cancers in a large proportion of patients.16,17
Most errors reported in assessing ECE by eMRI have been
false-negative results that occur because microscopic pene-
tration of the capsule is identified when pathology results are
reviewed, but cannot ultimately be detected by eMRI.
However, PCa with microscopic penetration of the capsule
without SVI or positive surgical margin might not differ from
pathologically diagnosed OCD treated with radical prostatec-
tomy8,9 in the disease-free survival rate. In 36 patients,
capsular thickening, bulging, and minimal irregularity were
interpreted as possible capsular penetration or seminal vesicle
involvement. However, upon review of final pathology results,
only 12 patients were identified as ECE or SVI (sensitivity
33%). Importantly, the necessity to obtain a highly specific
diagnosis precludes the type of less-rigorous ‘possible T3’
sometimes diagnosed by eMRI, and is highly beneficial in
helping patients avoid undergoing neurovascular bundle
preservation prostatectomy.
Previous studies found that eMRI had a low sensitivity and
accuracy for predicting locally advanced PCa. Our analyses
showed that the sensitivity, specificity, and accuracy of eMRI
was 25%, 70.73%, and 68.09% for cT3a PCa; and 35.29%,
96.1%, and 85.11% for tumors at the cT3b stage. The eMRI
was limited in its ability to distinguish microscopic invasion of
prostate cancer.
Our study also found a low sensitivity and accuracy of
eMRI diagnoses for the prediction of locally advanced PCa,Table 4a
Area under the receiver operating characteristic curve in clinical stage T2.
Area Standard
error
p 95% confidence
interval
PSA 0.631 0.079 0.118 0.476e0.787
Gleason score 0.727 0.077 0.007 0.577e0.878
Gleason grade 0.699 0.082 0.018 0.538e0.860similar to previously published studies. One explanation for
the low sensitivity of eMRI for cT3 stage tumors may be
associated with the difficulty in detection of microscopic
invasion. We combined the preoperative serum PSA with the
eMRI for the diagnoses of cT3 stage tumors, and successfully
improved imaging sensitivity from 41.38% to 83.33%
( p ¼ 0.035) and accuracy from 56.38% to 80.56%
( p ¼ 0.019).
For patients with cT3 PCa, it is generally accepted that
radiation therapy, with or without hormonal therapy, should be
considered as first line intervention. Recently, surgical treat-
ment has been employed for selected cases with a low risk of
advanced disease. Accurate preoperative staging could also
assist urologists in deciding whether or not to preserve the
neurovascular bundles.
In our prospective study, the sensitivity, specificity, and
accuracy (63.08%, 41.38%, and 56.38%) of eMRI diagnoses
for cT2 PCa were unsatisfactory. Of PCa patients who were
predicted to have OCD tumors, 29.31% (17/58) were proven to
be stage pT3 PCa. Additionally, the Gleason grade of prostate
biopsies were significantly higher than those subjects with pT2
tumors, but PSA level was not statistically different between
pT2 and pT3 PCa patients. Integrating the Gleason grade from
prostate biopsy significantly improved the sensitivity (90.24%,
p ¼ 0.004) and accuracy (79.31%, p ¼ 0.007) of eMRI
diagnoses in cT2 stage tumors.
It is interesting to note that each parameter varied in
importance, depending upon the clinical stage analysed. The
Gleason grade from prostate biopsy is important for cT2 PCa,
but not for cT3 tumors. Otherwise, the preoperative PSA levelsTable 4b
Area under the receiver operating characteristic curve in clinical stage T3.
Area Standard
error
p 95% confidence
interval
PSA 0.878 0.059 <0.001 0.763e0.994
Gleason score 0.668 0.102 0.104 0.469e0.868
Gleason grade 0.694 0.102 0.060 0.494e0.895
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but not for the cT2 tumors. The working hypothetical theory
indicated that locally advanced PCa patients initially have
higher levels of PSA, and play a key role in improving the
discriminative ability of eMRI to predict ECE or SVI.
However, the PCa subjects of clinical OCD have no significant
preliminary PSA levels, so pathological factors such as
Gleason score were pivotal in improving the clinical diag-
nostic ability of eMRI. The recent study of Roethke et al
concluded that eMRI is effective in predicting ECE in an
intermediate to high-risk group,18 which is in accordance with
our result. The eMRI can more reliably predict locally
advanced PCa compared with pelvic phase-array MRI at 1.5 T
scan.19,20 To date, no endorectal coil is available for 3 T
imaging; 1.5 T scan using combined endorectal coil is still the
most effective for PCa, and is equal to the pelvic phase-array
MRI at 3 T scan.14,15,20e23 In combination with preoperative
parameters, including PSA and the Gleason score from pros-
tate biopsy may offer the better predictive value of eMRI
diagnoses in OCD or locally advanced PCa.
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